Magellan Asset Management Ltd Takes Position in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Magellan Asset Management acquired 570,409 Zimmer Biomet shares worth approximately $49.1 million, giving it a 0.30% stake. Institutional investors and hedge funds collectively own 88.89% of the company.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in adjusted EPS versus the $2.01 consensus and $2.18 billion in revenue, up 4.8% year over year. Management set fiscal 2026 EPS guidance at $8.47–$8.59.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $104.42; recent target changes ranged from $90 to $106.

Magellan Asset Management Ltd acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 570,409 shares of the medical equipment provider's stock, valued at approximately $49,107,000. Magellan Asset Management Ltd owned 0.30% of Zimmer Biomet as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Bank of Nova Scotia acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $1,483,000. Commerce Bank bought a new stake in shares of Zimmer Biomet in the second quarter valued at about $1,114,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Zimmer Biomet during the second quarter worth approximately $628,000. Evolve Private Wealth LLC acquired a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $313,000. Finally, Westpac Banking Corp bought a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $149,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.0%

ZBH stock opened at $101.01 on Monday. The stock has a fifty day moving average of $92.64 and a 200-day moving average of $91.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The company has a market capitalization of $19.27 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 2.75 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the company earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Analysts Set New Price Targets

ZBH has been the topic of a number of recent research reports. Barclays lowered their price objective on Zimmer Biomet from $100.00 to $94.00 and set an "underweight" rating on the stock in a research note on Wednesday, April 29th. Canaccord Genuity Group increased their target price on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Zacks Research cut Zimmer Biomet from a "hold" rating to a "strong sell" rating in a research note on Monday, July 27th. Truist Financial upped their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a "hold" rating in a report on Thursday, August 6th. Finally, Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $104.42.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company's stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source